The Food and Drug Administration (FDA) has approved a new drug for the treatment of moderate to severe plaque psoriasis. About 8 million adults in the United States have psoriasis with the most common type being plaque psoriasis. The drug, called deucravacitinib, is the first TYK2 inhibitor approved for the treatment of any disease. It will be […]
